Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Comparative Transcriptome Analyses in Mantle Cell Lymphoma (MCL): Evidence of E2F1 As a Major Target in Aggressive Blastoid MCL Model

Jusuf Imeri, Paul Marcoux, Christophe Desterke, Amen Allah Nasr, Radhia M'kacher, Annelise Bennaceur Griscelli, Ali Turhan

Blood (2023) 142 (Supplement 1): 5731.

https://doi.org/10.1182/blood-2023-174618

Published: 2023

Journal Articles

Single Cell Analysis of Genes Involved in Asymmetric Hematopoietic Stem Cell (HSC) Division in Chronic Myeloid Leukemia (CML) : Evidence of the Regulation of Tetraspanin CD63 during Leukemia Progression

Christophe Desterke, Annelise Bennaceur Griscelli, Ali Turhan

Blood (2023) 142 (Supplement 1): 3159.

https://doi.org/10.1182/blood-2023-174622

Published: 2023

Journal Articles

Chimeric Antigen-Receptor (CAR)-Engineered Natural Killer (NK) Cells Targeting Chronic Myeloid Leukemia (CML) Blast Crisis

Jusuf Imeri, Paul Marcoux, Matthias Huyghe, Christophe Desterke, Daianne Fantacini, Frank Griscelli, Dimas T. Covas, Lucas Edouardo Botelho de Souza, Annelise Bennaceur Griscelli, Ali Turhan

Blood (2023) 142 (Supplement 1): 4514.

https://doi.org/10.1182/blood-2023-174620

Published: 2023

Journal Articles

Long-term follow-up of subtotal splenectomy for hereditary spherocytosis: a single-center study

Thomas Pincez, Corinne Guitton, Frédéric Gauthier, Guénolée de Lambert, Véronique Picard, Madeleine Fénéant-Thibault, Ali Turhan, Narla Mohandas, Gil Tchernia, Loïc Garçon

Blood (2016) 127 (12): 1616–1618.

https://doi.org/10.1182/blood-2015-11-679357

Published: 2016

Journal Articles

Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase

Clémence Roux, Franck-Emmanuel Nicolini, Delphine Rea, Mathilde Niault, Luigina Mollica, Françoise Berger, Catherine Chassagne-Clément, Isabelle Tigaud, Michel Tulliez, Stéphane Giraudier, Ali Turhan, Philippe Rousselot, Laurence Legros

Blood (2013) 122 (17): 3082–3084.

https://doi.org/10.1182/blood-2013-07-513879

Published: 2013

Journal Articles

Properties of CD34 + CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

Xiaoyan Jiang, Donna Forrest, Franck Nicolini, Ali Turhan, Joelle Guilhot, Calvin Yip, Tessa Holyoake, Heather Jorgensen, Karen Lambie, Kyi Min Saw, Emily Pang, Ranko Vukovic, Paeta Lehn, Ashley Ringrose, Miao Yu, Ryan R. Brinkman, Clay Smith, Allen Eaves, Connie Eaves

Blood (2010) 116 (12): 2112–2121.

https://doi.org/10.1182/blood-2009-05-222471

Published: 2010

Includes: Supplemental data

Journal Articles

Homo-Harringtonine (Omacetaxine mepesuccinate) Induces a Dramatic and Sustained Reduction of BCR-ABL T315I mutated Transcripts in Chronic Phase Chronic Myelogenous Leukemia Patients Resistant to Tyrosine Kinase Inhibitors.

Franck Nicolini, MD, PhD, Laurence Legros, MD, PhD, Lydia Roy, MD, PhD, Jean-Claude Chomel, MD, Kaddour Chabane, BSc, Sophie Ducastelle, MD, Selim Corm, MD, Mauricette Michallet, MD, PhD, Francois Guilhot, MD, Ali Turhan, MD, PhD, Sandrine Hayette, PhD

Blood (2008) 112 (11): 1103.

https://doi.org/10.1182/blood.V112.11.1103.1103

Published: 2008

Journal Articles

Interaction of a Novel Signaling Protein (AHI-1) with BCR-ABL Modulates BCR-ABL Transforming Activity and Imatinib Response of Chronic Myeloid Leukemia Progenitor Cells.

Yun Zhao, PhD, Leon Zhou, MS, Ashley Ringrose, BS, Ann E.-J. Lin, BS, Erin Kennah, MS, Guoqing Sheng, PhD, Xiao-Jiang Li, PhD, Ali Turhan, PhD, Xiaoyan Jiang, MD, PhD

Blood (2007) 110 (11): 467.

https://doi.org/10.1182/blood.V110.11.467.467

Published: 2007

Journal Articles

Chronic Myeloid Leukemia Stem Cells Possess Unique Properties That Predict Intrinsic and Acquired Resistance to Imatinib Mesylate.

Xiaoyan Jiang, MD, PhD, Yun Zhao, PhD, Clayton Smith, MD, Maura Gasparetto, MD, Kyi Min Saw, Ali Turhan, MD, PhD, Allen Eaves, MD, PhD, Connie Eaves, PhD

Blood (2006) 108 (11): 752.

https://doi.org/10.1182/blood.V108.11.752.752

Published: 2006

Journal Articles

Atypical BCR-ABL Transcripts Chronic Myelogenous Leukemias Show Particular Features, and Their Classical Worse Prognosis Seems Abrogated by Imatinib Mesylate. A Retrospective Analysis of 22 Patients, on the Behalf of the French Intergroup of CML (Fi(ϕ)-LMC Group).

Franck E. Nicolini, MD, PhD, Nathalie Grardel, MD, Sandrine Hayette, PhD, Jean-Michel Cayuela, MD, Agnès Buzyn, MD, PhD, Eric Delabesse, MD, Christian Bastard, MD, Odile Blanchet, MD, Nathalie Sorel, PhD, Marie-Josée Mozziconacci, MD, Ali Turhan, MD, PhD, Virginie Eclache, MD, François-Xavier Mahon, MD, PhD, Nicole Dastugue, MD, Eric Legac, MD, Marie-Pierre Gaub, MD, Sélim Corm, MD, Claude Preudhomme, MD, PhD

Blood (2005) 106 (11): 3285.

https://doi.org/10.1182/blood.V106.11.3285.3285

Published: 2005

NARROW

Comparative Transcriptome Analyses in Mantle Cell Lymphoma (MCL): Evidence of E2F1 As a Major Target in Aggressive Blastoid MCL Model

Single Cell Analysis of Genes Involved in Asymmetric Hematopoietic Stem Cell (HSC) Division in Chronic Myeloid Leukemia (CML) : Evidence of the Regulation of Tetraspanin CD63 during Leukemia Progression

Chimeric Antigen-Receptor (CAR)-Engineered Natural Killer (NK) Cells Targeting Chronic Myeloid Leukemia (CML) Blast Crisis

Long-term follow-up of subtotal splenectomy for hereditary spherocytosis: a single-center study

Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase

Properties of CD34 + CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

Homo-Harringtonine (Omacetaxine mepesuccinate) Induces a Dramatic and Sustained Reduction of BCR-ABL T315I mutated Transcripts in Chronic Phase Chronic Myelogenous Leukemia Patients Resistant to Tyrosine Kinase Inhibitors.

Interaction of a Novel Signaling Protein (AHI-1) with BCR-ABL Modulates BCR-ABL Transforming Activity and Imatinib Response of Chronic Myeloid Leukemia Progenitor Cells.

Chronic Myeloid Leukemia Stem Cells Possess Unique Properties That Predict Intrinsic and Acquired Resistance to Imatinib Mesylate.

Atypical BCR-ABL Transcripts Chronic Myelogenous Leukemias Show Particular Features, and Their Classical Worse Prognosis Seems Abrogated by Imatinib Mesylate. A Retrospective Analysis of 22 Patients, on the Behalf of the French Intergroup of CML (Fi(ϕ)-LMC Group).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only